CRISPR Therapeutics ($CRSP) Impressive Stock Performance

CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their blood disorders candidate, exacel, and investors bet on potential regulatory approvals to follow.

All of this marks just the beginning of a great opportunity for long-term investors. Let's check out three reasons to buy CRISPR Therapeutics like there's no tomorrow.

CRISPR Therapeutics recently said it's shifting its focus to its next-generation immuno-oncology candidates and dropping its initial ones -- including a candidate that was in late-stage development.

Technical Analysis
CRISPR Therapeutics has broken the ceiling of the falling trend. CRSP is trading near the top of its 52-week range and above its 200-day simple moving average.
The pivot points show that the current price is above the pivot point of 61.59 USD, indicating a bullish bias.
Investors have been pushing the share price higher, and the stock still appears to have upward momentum.